# EDC Platform Comparison

Reference comparison of the major electronic data capture (EDC) platforms used in clinical research. **Verify current platform capabilities, 21 CFR Part 11 module status, integration options, and pricing directly with vendors before selection.** Vendor capabilities and editions evolve rapidly.

## Contents

- How to read this comparison
- REDCap
- Medidata Rave
- Veeva Vault EDC
- Castor
- OpenClinica
- Clinical Ink
- Oracle Clinical / RDC
- Decision framework
- Verification expectations

---

## How to read this comparison

EDC selection is not "platform X is better than platform Y." It is fit between platform and study type, sponsor capability, regulatory scope, integration footprint, and operating budget. Strengths and weaknesses below are at the category level; specific edition/module/version may differ.

Common evaluation dimensions:

- **Regulatory scope** — FDA-regulated trials, academic / IIS, observational, registries, post-market, DCT.
- **21 CFR Part 11 posture** — out-of-the-box vs. configurable vs. requires institutional hardening.
- **eCRF authoring** — speed of build, complexity supported, mid-study amendment handling.
- **CDISC alignment** — CDASH at design, SDTM mapping support.
- **Integrations** — IRT, eConsent, ePRO, lab, safety database, eTMF, CTMS, FHIR/EHR.
- **Operational ergonomics** — site UX, data manager UX, monitor UX.
- **Cost model** — per-study, per-eCRF, per-subject, per-user, enterprise.
- **Vendor / community support** — global presence, regulatory expertise.

---

## REDCap

**Origin**: Vanderbilt University; distributed via the REDCap Consortium to academic and nonprofit member institutions.

**Strengths**:
- Rapid eCRF build by non-developers; familiar to clinical research coordinators.
- Free for consortium members; broad academic adoption.
- Active community library of instruments and templates.
- API for integration; survey module for ePRO.
- Multi-language support; widely deployed globally.

**Considerations**:
- **21 CFR Part 11 capability**: requires institutional hardening (validated installation, controlled user provisioning, audit trail enabled, signature manifestation, validated change control, SOPs). The REDCap Consortium publishes guidance; verify the current Part 11 module status with your institutional REDCap administrator.
- Industry-sponsored multi-site trials typically require additional validation overhead vs. purpose-built sponsor platforms.
- Complex randomization, drug supply, and adaptive design require external integrations.
- Reporting and standard CDISC export require tooling beyond out-of-the-box.

**Typical fit**: Academic IIS (investigator-initiated studies), single-site or small consortium trials, observational studies, registries, quality improvement, surveys.

---

## Medidata Rave

**Origin**: Medidata Solutions (now part of Dassault Systèmes); industry-standard sponsor-led trials.

**Strengths**:
- Purpose-built for sponsor-led, multi-site, FDA-regulated trials.
- 21 CFR Part 11 controls and validation included; widely accepted by FDA, EMA, PMDA reviewers.
- Mature integration ecosystem (Medidata RTSM/IRT, Medidata Patient Cloud / Detect for ePRO and digital trials, Medidata eConsent, Medidata Detect for risk-based monitoring).
- Standard SDTM export tooling.
- Large, well-staffed CRO and sponsor user base.

**Considerations**:
- Cost is meaningfully higher than academic platforms.
- Configuration / build typically requires Medidata-experienced developers or partners.
- Less attractive for very small or low-budget studies.

**Typical fit**: Phase 1-4 industry-sponsored trials, CRO-managed studies, global multi-site programs.

---

## Veeva Vault EDC

**Origin**: Veeva Systems; newer entrant integrated with Veeva Vault CTMS, eTMF, eConsent, ePRO, RIM, and other Vault applications.

**Strengths**:
- Native integration across the Vault platform (EDC + CTMS + eTMF + eConsent + ePRO).
- Modern UX relative to legacy EDC.
- 21 CFR Part 11 controls and validation included.
- Strong sponsor and CRO adoption growth.

**Considerations**:
- Newer than Rave; mileage varies by therapeutic area and study complexity.
- Single-vendor risk if locking into the full Vault stack.
- Verify current feature parity for any specific functionality (e.g., complex randomization, adaptive design) against Rave or legacy systems.

**Typical fit**: Sponsor-led trials where the broader Vault stack (CTMS, eTMF) is also in use; biotechs standardizing on a single vendor.

---

## Castor

**Origin**: Castor EDC; mid-market and academic.

**Strengths**:
- Modern web UX.
- Faster eCRF build than enterprise platforms.
- 21 CFR Part 11 and GDPR controls.
- Combined EDC + ePRO + eConsent offerings.
- Often selected by mid-size sponsors, academic medical centers running industry-sponsored work, and digital-health-oriented companies.

**Considerations**:
- Smaller installed base than Rave / Vault for very large global Phase 3 programs.
- Verify integration availability for any specific IRT, lab, or safety database.

**Typical fit**: Mid-market trials, academic medical centers running externally-sponsored trials, digital-health and DCT-oriented studies.

---

## OpenClinica

**Origin**: OpenClinica LLC; open-source roots, commercial editions.

**Strengths**:
- Open-source / commercial dual model.
- Used widely in academic, global health, and lower-resource settings.
- 21 CFR Part 11 and HIPAA-capable in commercial editions (verify edition).
- ePRO module available.

**Considerations**:
- Sponsor adoption is concentrated in academic and global health; verify acceptance with regulators / industry partners.
- Configuration / customization typically requires technical expertise.

**Typical fit**: Academic, global health, low-resource settings, NIH-funded research, observational studies.

---

## Clinical Ink

**Origin**: Clinical Ink; DCT-oriented and eSource-focused.

**Strengths**:
- Strong eSource and direct-to-tablet data capture posture.
- Native ePRO / eCOA / eConsent capabilities.
- Marketed for decentralized and hybrid trials.

**Considerations**:
- Smaller installed base than Rave / Vault for traditional Phase 3.
- Verify integration footprint with sponsor IRT, lab, and safety database.

**Typical fit**: DCT and hybrid trials, sponsor programs prioritizing tablet-based site workflow.

---

## Oracle Clinical / RDC

**Origin**: Oracle Health Sciences; long-standing enterprise platform.

**Strengths**:
- Mature, deeply integrated within Oracle ecosystem.
- Significant installed base at large pharma.

**Considerations**:
- Aging UX; verify current platform roadmap and supported versions with Oracle.
- New starts typically choose modern alternatives.

**Typical fit**: Existing Oracle-standardized large pharma sponsors, legacy study migration.

---

## Decision framework

| Study profile | Typical candidate platforms |
|---------------|------------------------------|
| Academic IIS, single-site or small consortium | REDCap (with Part 11 hardening for FDA-regulated work), OpenClinica |
| Large sponsor-led global Phase 3 | Medidata Rave, Veeva Vault EDC |
| Sponsor program standardizing on Vault | Veeva Vault EDC + Vault CTMS + Vault eTMF |
| Mid-market biotech | Castor, Vault EDC, Rave |
| Decentralized / hybrid trial | Medidata (Patient Cloud), Clinical Ink, Castor |
| Observational / registry | REDCap, OpenClinica, Castor |
| Post-marketing surveillance | Veeva, Medidata, or registry-specific platforms |
| Global health / low-resource | OpenClinica, REDCap |

Match the platform to the regulatory bar, integration needs, and operational scale — not to vendor marketing.

---

## Verification expectations

Before platform selection or contract:

1. Verify current 21 CFR Part 11 module / certification posture with the vendor (do not assume from prior project knowledge).
2. Verify CDISC export capability and version coverage (CDASH, SDTM, Define-XML).
3. Verify integration availability for required ancillary systems (IRT, eConsent, ePRO, lab, safety, eTMF, CTMS).
4. Verify GDPR posture if EU subjects are in scope.
5. Verify validation documentation availability (IQ/OQ/PQ templates, vendor audit reports).
6. Verify current pricing model and cost across study lifecycle (build, conduct, lock, archive).
7. Verify support footprint in regions where study sites will operate.
8. Pilot eCRF build with the actual study team before committing.

Vendor capabilities, editions, and pricing change. Always verify directly with the vendor against the current product.
